Advertisement

Infectious Agents Associated with Mesothelioma

  • Nguyen Son Lam
  • Nguyen Van Tho
  • Tran Dinh Thanh
  • Yasutaka Nakano
Chapter
Part of the Current Cancer Research book series (CUCR)

Abstract

Malignant mesothelioma is a rare but fatal disease which arises from the epithelial lining of the pleura, peritoneum, pericardium, and tunica vaginalis. Malignant pleural mesothelioma (MPM) is the most common form. The global incidence of MPM has risen steadily over the past decade and is predicted to peak in 2020. The mechanism of carcinogenesis in MPM is multifactorial. A history of long-term exposure to asbestos is the established cause of MPM. Cytolysins such as Pneumolysin, Streptolysin O, Intermedilysin, Mitilysin, and Lectinolysin secreted by the airways microbiota may create pores through which asbestos can pass through the airways, reach the visceral pleura and cause MPM. However, MPM may result from other factors such as genetics, erionite, chest wall radiation, and simian virus 40 (SV40) that may work alone or in combination. The roles of SV40 in malignant mesothelioma is still controversial. More studies are needed to explain the wide disparity in the prevalence of SV40 in mesothelioma tissues reported by different laboratories or regions. In this chapter we discuss about how infectious agents may be associated with malignant mesothelioma.

Keywords

Immunohistochemistry Malignant mesothelioma Pleural Simian virus 40 Tumor Viral carcinogenesis Viral infection 

References

  1. 1.
    Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17:260–271PubMedPubMedCentralGoogle Scholar
  2. 2.
    Robinson BM (2012) Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 1(4):491–496.  https://doi.org/10.3978/j.issn.2225-319X.2012.11.04PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Pechoux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35(3):479–495.  https://doi.org/10.1183/09031936.00063109PubMedCrossRefGoogle Scholar
  4. 4.
    Park EK, Takahashi K, Hoshuyama T, Cheng TJ, Delgermaa V, Le GV, Sorahan T (2011) Global magnitude of reported and unreported mesothelioma. Environ Health Perspect 119(4):514–518.  https://doi.org/10.1289/ehp.1002845PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, Gadgeel S (2016) Mesothelioma in the United States: a surveillance, epidemiology, and end results (SEER)-medicare investigation of treatment patterns and overall survival. Clin Epidemiol 8:743–750.  https://doi.org/10.2147/CLEP.S105396PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Cugell DW, Kamp DW (2004) Asbestos and the pleura: a review. Chest 125(3):1103–1117PubMedCrossRefGoogle Scholar
  7. 7.
    McDonald AD, McDonald JC (1980) Malignant mesothelioma in North America. Cancer 46(7):1650–1656PubMedCrossRefGoogle Scholar
  8. 8.
    Yang H, Testa JR, Carbone M (2008) Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options in Oncol 9(2–3):147–157.  https://doi.org/10.1007/s11864-008-0067-zCrossRefGoogle Scholar
  9. 9.
    Thanh TD, Tho NV, Lam NS, Dung NH, Tabata C, Nakano Y (2016) Simian virus 40 may be associated with developing malignant pleural mesothelioma. Oncol Lett 11(3):2051–2056.  https://doi.org/10.3892/ol.2016.4174PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD (2015) Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Lung Cancer 88(3):344–348.  https://doi.org/10.1016/j.lungcan.2015.03.005PubMedCrossRefGoogle Scholar
  11. 11.
    Milano MT, Zhang H (2010) Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 5(11):1841–1848.  https://doi.org/10.1097/JTO.0b013e3181f1cf2bPubMedCrossRefGoogle Scholar
  12. 12.
    Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I (2016) Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev 25(142):472–486.  https://doi.org/10.1183/16000617.0063-2016PubMedCrossRefGoogle Scholar
  13. 13.
    Odisio EG, Marom EM, Shroff GS, Wu CC, Apa B, Truong MT, Benveniste MF (2017) Malignant pleural mesothelioma: diagnosis, staging, pitfalls and follow-up. Sem Ultrasound CT MRI 38:559–570.  https://doi.org/10.1053/j.sult.2017.07.006CrossRefGoogle Scholar
  14. 14.
    Bibby AC, Maskell NA (2016) Pleural biopsies in undiagnosed pleural effusions; abrams vs image-guided vs thoracoscopic biopsies. Curr Opin Pulm Med 22(4):392–398.  https://doi.org/10.1097/MCP.0000000000000258PubMedCrossRefGoogle Scholar
  15. 15.
    Boutin C, Rey F (1993) Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer 72(2):389–393PubMedCrossRefGoogle Scholar
  16. 16.
    Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K (2007) Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 57(4):190–199.  https://doi.org/10.1111/j.1440-1827.2007.02080.xPubMedCrossRefGoogle Scholar
  17. 17.
    Sandeck HP, Roe OD, Kjaerheim K, Willen H, Larsson E (2010) Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry. Diagn Pathol 5:47.  https://doi.org/10.1186/1746-1596-5-47PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Husain AN, Colby TV, Ordonez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Salle F, Gibbs A, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, Wick MR (2017) Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 142:89–108.  https://doi.org/10.5858/arpa.2017-0124-RAPubMedCrossRefGoogle Scholar
  19. 19.
    Pastan I, Hassan R (2014) Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 74(11):2907–2912.  https://doi.org/10.1158/0008-5472.CAN-14-0337PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA (2014) Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res 20(23):5927–5936.  https://doi.org/10.1158/1078-0432.CCR-14-0804PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Jahan T, Hassan R, Alley E, Kindler H, Antonia S, Whiting C, Coussens L, Murphy AL, Thomas A, Brockstedt DG (2016) 208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): results from a phase 1b trial. J Thorac Oncol 11(4 Suppl):S156.  https://doi.org/10.1016/S1556-0864(16)30330-6CrossRefGoogle Scholar
  22. 22.
    Miserocchi G, Sancini G, Mantegazza F, Chiappino G (2008) Translocation pathways for inhaled asbestos fibers. Environ Health 7:4.  https://doi.org/10.1186/1476-069X-7-4PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Magouliotis DE, Tasiopoulou VS, Molyvdas PA, Gourgoulianis KI, Hatzoglou C, Zarogiannis SG (2014) Airways microbiota: hidden Trojan horses in asbestos exposed individuals? Med Hypotheses 83(5):537–540.  https://doi.org/10.1016/j.mehy.2014.09.006PubMedCrossRefGoogle Scholar
  24. 24.
    Geny B, Popoff MR (2006) Bacterial protein toxins and lipids: pore formation or toxin entry into cells. Biol Cell 98(11):667–678.  https://doi.org/10.1042/BC20050082PubMedCrossRefGoogle Scholar
  25. 25.
    Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935):1306–1309PubMedCrossRefGoogle Scholar
  26. 26.
    Grove CS, Lee YC (2002) Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 8(4):294–301PubMedCrossRefGoogle Scholar
  27. 27.
    Koff JL, Shao MX, Ueki IF, Nadel JA (2008) Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium. Am J Physiol Lung Cell Mol Physiol 294(6):L1068–L1075.  https://doi.org/10.1152/ajplung.00025.2008PubMedCrossRefGoogle Scholar
  28. 28.
    Wornle M, Sauter M, Kastenmuller K, Ribeiro A, Roeder M, Mussack T, Ladurner R, Sitter T (2009) Role of viral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesothelioma. Cell Biol Int 33(2):180–186.  https://doi.org/10.1016/j.cellbi.2008.10.011PubMedCrossRefGoogle Scholar
  29. 29.
    Ahuja D, Saenz-Robles MT, Pipas JM (2005) SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24(52):7729–7745.  https://doi.org/10.1038/sj.onc.1209046PubMedCrossRefGoogle Scholar
  30. 30.
    Carbone M, Pass HI (2006) Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition. J Thorac Oncol 1(2):169–171PubMedCrossRefGoogle Scholar
  31. 31.
    Ramael M, Nagels J, Heylen H, De Schepper S, Paulussen J, De Maeyer M, Van Haesendonck C (1999) Detection of SV40 like viral DNA and viral antigens in malignant pleural mesothelioma. Eur Respir J 14(6):1381–1386PubMedCrossRefGoogle Scholar
  32. 32.
    Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, Tognon M (2004) Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology 318(1):1–9PubMedCrossRefGoogle Scholar
  33. 33.
    Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson RB Jr, Bourbeau P, Carroll KC, Kehl SC, Dunne WM, Robinson-Dunn B, Schwartzman JD, Chapin KC, Snyder JW, Forbes BA, Patel R, Rosenblatt JE, Pritt BS (2013) A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) (a). Clin Infect Dis 57(4):e22–e121.  https://doi.org/10.1093/cid/cit278PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353(15):1591–1603.  https://doi.org/10.1056/NEJMra050152PubMedCrossRefGoogle Scholar
  35. 35.
    Wilkinson KA, Wilkinson RJ, Pathan A, Ewer K, Prakash M, Klenerman P, Maskell N, Davies R, Pasvol G, Lalvani A (2005) Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. Clin Infect Dis 40(1):184–187.  https://doi.org/10.1086/426139PubMedCrossRefGoogle Scholar
  36. 36.
    Shah KV (2004) Simian virus 40 and human disease. J Infect Dis 190(12):2061–2064.  https://doi.org/10.1086/425999PubMedCrossRefGoogle Scholar
  37. 37.
    Mossman BT, Gruenert DC (2002) SV40, growth factors, and mesothelioma: another piece of the puzzle. Am J Respir Cell Mol Biol 26(2):167–170.  https://doi.org/10.1165/ajrcmb.26.2.f229PubMedCrossRefGoogle Scholar
  38. 38.
    Cutrone R, Lednicky J, Dunn G, Rizzo P, Bocchetta M, Chumakov K, Minor P, Carbone M (2005) Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res 65(22):10273–10279.  https://doi.org/10.1158/0008-5472.CAN-05-2028PubMedCrossRefGoogle Scholar
  39. 39.
    Carbone M, Yang H (2017) Mesothelioma: recent highlights. Ann Transl Med 5(11):238.  https://doi.org/10.21037/atm.2017.04.29PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Cicala C, Pompetti F, Carbone M (1993) SV40 induces mesotheliomas in hamsters. Am J Pathol 142(5):1524–1533PubMedPubMedCentralGoogle Scholar
  41. 41.
    Carbone M, Burck C, Rdzanek M, Rudzinski J, Cutrone R, Bocchetta M (2003a) Different susceptibility of human mesothelial cells to polyomavirus infection and malignant transformation. Cancer Res 63(19):6125–6129PubMedGoogle Scholar
  42. 42.
    Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, Vacek P, Ramos-Nino M, Mossman BT, Pass HI, Carbone M (2006) Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci U S A 103(38):14128–14133.  https://doi.org/10.1073/pnas.0604544103PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Comar M, Zanotta N, Pesel G, Visconti P, Maestri I, Rinaldi R, Crovella S, Cortale M, De Zotti R, Bovenzi M (2012) Asbestos and SV40 in malignant pleural mesothelioma from a hyperendemic area of North-Eastern Italy. Tumori 98(2):210–214.  https://doi.org/10.1700/1088.11931PubMedCrossRefGoogle Scholar
  44. 44.
    Jin M, Sawa H, Suzuki T, Shimizu K, Makino Y, Tanaka S, Nojima T, Fujioka Y, Asamoto M, Suko N, Fujita M, Nagashima K (2004) Investigation of simian virus 40 large T antigen in 18 autopsied malignant mesothelioma patients in Japan. J Med Virol 74(4):668–676.  https://doi.org/10.1002/jmv.20219PubMedCrossRefGoogle Scholar
  45. 45.
    Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M (2008) The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med 14(4):316–321.  https://doi.org/10.1097/MCP.0b013e3283018220PubMedCrossRefGoogle Scholar
  46. 46.
    Carbone M, Pass HI, Miele L, Bocchetta M (2003b) New developments about the association of SV40 with human mesothelioma. Oncogene 22(33):5173–5180.  https://doi.org/10.1038/sj.onc.1206552PubMedCrossRefGoogle Scholar
  47. 47.
    Bocchetta M, Eliasz S, De Marco MA, Rudzinski J, Zhang L, Carbone M (2008) The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res 68(4):1022–1029.  https://doi.org/10.1158/0008-5472.CAN-07-5203PubMedCrossRefGoogle Scholar
  48. 48.
    Hirvonen A, Mattson K, Karjalainen A, Ollikainen T, Tammilehto L, Hovi T, Vainio H, Pass HI, Di Resta I, Carbone M, Linnainmaa K (1999) Simian virus 40 (SV40)-like DNA sequences not detectable in Finnish mesothelioma patients not exposed to SV40-contaminated polio vaccines. Mol Carcinog 26(2):93–99PubMedCrossRefGoogle Scholar
  49. 49.
    De Rienzo A, Tor M, Sterman DH, Aksoy F, Albelda SM, Testa JR (2002) Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. J Cell Biochem 84(3):455–459PubMedCrossRefGoogle Scholar
  50. 50.
    Aoe K, Hiraki A, Murakami T, Toyooka S, Shivapurkar N, Gazdar AF, Sueoka N, Taguchi K, Kamei T, Takeyama H, Sugi K, Kishimoto T (2006) Infrequent existence of simian virus 40 large T antigen DNA in malignant mesothelioma in Japan. Cancer Sci 97(4):292–295.  https://doi.org/10.1111/j.1349-7006.2006.00171.xPubMedCrossRefGoogle Scholar
  51. 51.
    Lopez-Rios F, Illei PB, Rusch V, Ladanyi M (2004) Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364(9440):1157–1166.  https://doi.org/10.1016/S0140-6736(04)17102-XPubMedCrossRefGoogle Scholar
  52. 52.
    Eom M, Abdul-Ghafar J, Park SM, Han JH, Hong SW, Kwon KY, Ko ES, Kim L, Kim WS, Ha SY, Lee KY, Lee CH, Yoon HK, Choi YD, Chung MJ, Jung SH (2013) No detection of simian virus 40 in malignant mesothelioma in Korea. Korean J Pathol 47(2):124–129.  https://doi.org/10.4132/KoreanJPathol.2013.47.2.124PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Carbone M, Pass HI, Rizzo P, Marinetti M, Di Muzio M, Mew DJ, Levine AS, Procopio A (1994) Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 9(6):1781–1790PubMedGoogle Scholar
  54. 54.
    Simsir A, Fetsch P, Bedrossian CW, Ioffe OB, Abati A (2001) Absence of SV-40 large T antigen (tag) in malignant mesothelioma effusions: an immunocytochemical study. Diagn Cytopathol 25(4):203–207PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nguyen Son Lam
    • 1
  • Nguyen Van Tho
    • 2
  • Tran Dinh Thanh
    • 3
  • Yasutaka Nakano
    • 4
  1. 1.Department of PathologyPham Ngoc Thach HospitalHo Chi Minh CityVietnam
  2. 2.Department of Tuberculosis and Lung Diseases, Faculty of MedicineUniversity of Medicine and Pharmacy at Ho Chi Minh CityHo Chi Minh CityVietnam
  3. 3.Department of OncologyPham Ngoc Thach HospitalHo Chi Minh CityVietnam
  4. 4.Division of Respiratory Medicine, Department of MedicineShiga University of Medical ScienceShigaJapan

Personalised recommendations